$21.89
0.28[1.30%]
At close: Jun 3
$21.89
0[0.00%]
After Hours: 4:00PM EDT
Dianthus Therapeutics
(NASDAQ:DNTH)Latest News for Dianthus Therapeutics Stock (NASDAQ:DNTH)
Dianthus Therapeutics Stock (NASDAQ: DNTH)
Categories: All
Thursday, May 16, 2024
Friday, May 10, 2024
Thursday, May 09, 2024
Thursday, April 18, 2024
Friday, March 22, 2024
- Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day SessionAvi Kapoor - Mar 22, 2024, 2:39PM
- Dianthus Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results. Also, Wedbush maintained an Outperform rating on the stock and raised its price target from $24 to $33.Benzinga Newsdesk - Mar 22, 2024, 10:54AM
- Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On FridayAvi Kapoor - Mar 22, 2024, 10:08AM
- Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $33Benzinga Newsdesk - Mar 22, 2024, 10:03AM
Thursday, March 21, 2024
Thursday, February 15, 2024
Wednesday, January 31, 2024
Friday, January 26, 2024
Monday, January 22, 2024
- Why Dianthus Therapeutics (DNTH) Stock Is Exploding HigherHenry Khederian - Jan 22, 2024, 4:18PM
- Dianthus Therapeutics shares are trading higher after the company announced a $230 million private placement.Benzinga Newsdesk - Jan 22, 2024, 12:54PM
- Dianthus Therapeutics Enters Agreement For Private Investment In Public Equity Financing That Is Expected To Result In Gross Proceeds Of $230MBenzinga Newsdesk - Jan 22, 2024, 7:43AM
Tuesday, December 26, 2023
Wednesday, November 22, 2023
Thursday, November 09, 2023
Friday, September 29, 2023
Thursday, September 28, 2023
- Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - AnalystVandana Singh - Sep 28, 2023, 3:33PM
- Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023Benzinga Insights - Sep 28, 2023, 11:00AM
- Raymond James Initiates Coverage On Dianthus Therapeutics with Outperform Rating, Announces Price Target of $24Benzinga Newsdesk - Sep 28, 2023, 9:14AM
Friday, September 22, 2023
Thursday, September 14, 2023
- Director at Dianthus Therapeutics, Inc. - Common Stock Acquires Company Stock Options Worth 6,500 SharesBenzinga Insights - Sep 14, 2023, 11:00AM
- Dianthus Therapeutics, Inc. - Common Stock Director Awarded $85K Worth of Stock OptionsBenzinga Insights - Sep 14, 2023, 11:00AM
- Board Member at Dianthus Therapeutics, Inc. - Common Stock Acquires Company Stock Options Worth 6,500 SharesBenzinga Insights - Sep 14, 2023, 11:00AM